Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Lê MP, et al. Among authors: chaix ml. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193. J Antimicrob Chemother. 2018. PMID: 29905808 Clinical Trial.
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. Marcelin AG, et al. Among authors: chaix ml. Antimicrob Agents Chemother. 2005 May;49(5):1720-6. doi: 10.1128/AAC.49.5.1720-1726.2005. Antimicrob Agents Chemother. 2005. PMID: 15855487 Free PMC article. Clinical Trial.
Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.
Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C; PRIMSTOP Study Group. Hoen B, et al. Among authors: chaix ml. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):307-16. doi: 10.1097/01.qai.0000182628.66713.31. J Acquir Immune Defic Syndr. 2005. PMID: 16249705 Clinical Trial.
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Peytavin G, Toure H, Menan H, Leroy V, Dabis F, Rouzioux C; Agence Nationale de Recherches sur le SIDA Ditrame Plus Study Group. Chaix ML, et al. J Infect Dis. 2006 Feb 15;193(4):482-7. doi: 10.1086/499966. Epub 2006 Jan 11. J Infect Dis. 2006. PMID: 16425126
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Amani-Bosse C, Menan H, Leroy V, Rouzioux C, Dabis F. Chaix ML, et al. Antimicrob Agents Chemother. 2007 Mar;51(3):896-901. doi: 10.1128/AAC.00910-06. Epub 2006 Dec 18. Antimicrob Agents Chemother. 2007. PMID: 17178792 Free PMC article. Clinical Trial.
335 results